ARMP Stock Forecast: Armata Pharmaceuticals, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for Armata Pharmaceuticals, Inc. is $18. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 86 of 100 as at 18 Nov 2026 — inside the top quartile.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Armata Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (97): Reported profit is backed by cash, and the company is not expanding recklessly.
Issuance (15): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
ARMP stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on ARMP, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 23 Sept 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 23 Feb 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 5 Jan 2026 | Jones Trading | Initiates | Buy | — |
| 19 May 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 19 Dec 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 14 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 12 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 15 Aug 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 11 July 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 8 May 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 22 Mar 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 14 Aug 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 12 May 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 17 Mar 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 7 Mar 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 22 Mar 2021 | HC Wainwright & Co. | Maintains | Buy | — |
| 15 May 2020 | H.C. Wainwright | Reiterates | Buy | — |
| 15 May 2020 | HC Wainwright & Co. | Reiterates | Buy | — |
| 20 Mar 2020 | H.C. Wainwright | Reiterates | Buy | — |
| 20 Mar 2020 | HC Wainwright & Co. | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for ARMP.
This page is one stock. Monday covers all of them.
ARMP appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
ARMP vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 19 Nov 2026, Armata Pharmaceuticals, Inc. returned −58.8% against +9.2% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
ARMP analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 13.1×
- Price / book
- —
- EV / EBITDA
- —
Cheaper than 10% of US stocks
- Revenue growth (YoY)
- 173.6%
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
Higher than 95% of US stocks
- Return on equity
- —
- Return on assets
- −25.1%
- Dividend yield
- —
Higher than 17% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Armata Pharmaceuticals, Inc. has a market value of $98.9M and an enterprise value of $332.2M.
Revenue in the twelve months to 31 Mar 2026: $0.0.
Net income over the same four quarters: −$282.6M.
Free cash flow in the twelve months to 31 Mar 2026: −$24.5M, after $506K of capital spending.
Armata Pharmaceuticals, Inc. employs 61 people.
Data provided by Twelve Data
ARMP and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at ARMP’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Armata Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about ARMP
What is the ARMP stock price forecast for 2026-2027?
The median 12-month analyst price target for Armata Pharmaceuticals, Inc. is $18, with estimates ranging from $15 to $20. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is ARMP stock a buy right now?
Of the 2 analysts covering Armata Pharmaceuticals, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Armata Pharmaceuticals, Inc. 86 out of 100 across roughly 4,300 US stocks as at 18 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank ARMP?
As at 18 Nov 2026, Armata Pharmaceuticals, Inc. ranks 86 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (97 of 100).
Will ARMP stock go up?
No one can know that. What the data says: the median 12-month target from 2 analysts is $18, and Ticker Nerd's factor model ranks Armata Pharmaceuticals, Inc. 86 out of 100 as at 18 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the ARMP stock forecast for 2030?
No analyst covering Armata Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ARMP are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $15 to $20 over the next 12 months.
How has ARMP stock performed over the past year?
Armata Pharmaceuticals, Inc. returned -58.8% over the 12 months to 19 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Armata Pharmaceuticals, Inc. do?
Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections. The company’s current work centers on phage-based medicines designed to target specific bacterial pathogens, with programs addressing infections such as Staphylococcus aureus bacteremia and Pseudomonas aeruginosa-related disease.
About Armata Pharmaceuticals, Inc.
Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections. The company’s current work centers on phage-based medicines designed to target specific bacterial pathogens, with programs addressing infections such as Staphylococcus aureus bacteremia and Pseudomonas aeruginosa-related disease. Its platform combines natural and synthetic bacteriophages with proprietary engineering, microbiological surveillance, and drug development capabilities to support product design, manufacturing, and clinical testing. Armata Pharmaceuticals operates as a specialist in infectious disease therapeutics, serving an important role in the broader biopharmaceutical market by advancing alternative approaches to conventional antibiotics.
CEO Dr. Deborah L. Birx M.D. · 61 employees · United States · https://www.armatapharma.com